Our Pipeline: Placing Better Outcomes Within Reach
NexImmune is acting with urgency to meet the needs of waiting patients by advancing our clinical pipeline of immunotherapies for cancer. We are also continuing our preclinical research on novel therapies that will create better outcomes for patients with other cancers and life-threatening conditions.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia(AML) after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in other disease areas, including autoimmune disorders and infectious disease.
In addition to our programs using the adoptive cell therapy modality, (our AIM ACT technology) we are also developing a next-generation off-the-shelf injectable modality (our AIM INJ technology). The AIM INJ modality is designed for direct injection or infusion to engage T cells directly inside the body without the need for ex vivo manufacturing, which we believe will result in greater ease of administration and a less complex and less expensive manufacturing process.
The following table summarizes our pipeline: